Treatment Plan to Provide Expanded Access to Stiripentol for Patients With Dravet Syndrome
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Know the risks and potential benefits of clinical studies and talk to your health care provider before participating.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
6 Months and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
6 months and older
Diagnosis of Dravet Syndrome with intractable seizures
Hypersensitivity to the active substance or to any of the excipients
Past history of psychoses in the form of episodes of delirium
Impaired hepatic and/or renal function, defined as creatinine >2 and/or transaminase >4xULN